[Biomarker analysis from a pathologist's view. Founding the rationale for personalised treatment of lung cancer]. / Biomarkeranalytik aus Sicht des Pathologen. Grundlage für eine rationale, personalisierte Tumortherapie am Beispiel von Lungenkrebs.
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
; 56(11): 1502-8, 2013 Nov.
Article
em De
| MEDLINE
| ID: mdl-24170079
ABSTRACT
The advent of genomic medicine and sequencing analysis of entire cancer genomes has rapidly improved our understanding of cancer genomics and has defined pathogenetic lesions initiating and driving cancer phenotypes in a causative manner. Moreover rapid development of small molecule inhibitors and highly selective biologicals provided effective tools to intervene with oncogenic signalling resulting from such lesions in the cancer genome. Thereby, the pathologist is now in the position to diagnose causative lesions in the cancer genome as molecular biomarkers directing the selection of patients for effective and highly selective therapies. If oncogenic driver lesions are vigorously validated preclinically and a useful diagnostic test is available, it is possible to provide a proof-of-concept at a very early stage of clinical drug development with the possibility of immediate personal benefit for participants in such phase I/II studies. This approach has significantly changed clinical testing and avoids testing proof for efficacy in large stage III clinical trials at a high failure rate. Therefore, our review summarises recent and paradigmatic progress in lung cancer biomarker diagnostics and defines academic and regulatory requirements for biomarker analysis and selective personalised therapies.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Farmacogenética
/
Biomarcadores Tumorais
/
Marcadores Genéticos
/
Patologia Molecular
/
Terapia de Alvo Molecular
/
Neoplasias Pulmonares
Tipo de estudo:
Diagnostic_studies
Limite:
Humans
Idioma:
De
Ano de publicação:
2013
Tipo de documento:
Article